Alloy therapeutics signs collaboration and license agreement with takeda to develop cell therapy platform

Tokyo & boston--(business wire)--alloy therapeutics inc. (“alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with takeda pharmaceutical company limited (tse:4502/nyse:tak “takeda”) to develop takeda's proprietary induced pluripotent stem cell (ipsc) derived car-t cell platform (icar-t) and ipsc-derived car-nk platform (icar-nk). alloy will focus on accelerating.
TAK Ratings Summary
TAK Quant Ranking